Data supporting a promising, new treatment for Cystic Fibrosis (CF) developed by Verona Pharma will be presented for the first time at the 28th Annual North American Cystic Fibrosis Conference (NACFC) in Atlanta, Georgia on October 9-11, 2014.
Verona Pharma’s key molecule, RPL554, is currently being evaluated in a phase two clinical trial for the treatment of COPD (Chronic obstructive pulmonary disease), but the company also believes that the therapy can treat CF as well. The company’s findings will be summarized in a presentation entitled “CFTR activation by the dual phosphodiesterase ¾ inhibitor RPL554 and the MRP4 inhibitor MK571.”
RPL554 can activate CFTR (short for cystic fibrosis transmembrane conductance regulator) in CF patients. Currently without a cure, the demand for new treatments for CF is high, and Verona Pharma will further evaluate their findings in pre-clinical model systems, working together with academic scientists.
- Disorders & Diseases
- Public Health
- Products & Treatment
- Department Management